Clinical trial
Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or…
NCT00006387 · Fox Chase Cancer Center, Other · Completed
Key facts
| NCT number | NCT00006387 |
|---|---|
| Title | Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer |
| Official title | A Phase I Study of RAS Peptide Vaccination in Patients With Advanced Pancreatic or Colorectal Adenocarcinoma |
| Lead sponsor | Fox Chase Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Pancreatic Cancer |
| Intervention type | Biological |
| Interventions | QS21, ras peptide cancer vaccine |
| Enrollment | 7 |
| Start date | Oct 1, 2000 |
| Primary completion | Jan 1, 2002 |
| Completion | Jan 1, 2002 |
| First posted | Jun 9, 2004 |
| Last update posted | Jul 11, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: